Anti-MSLN therapeutic antibody (Pre-made Amatuximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. It was developed by Morphotek, Inc. Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-020-1mg	1mg	3090
GMP-Bios-ab-020-10mg	10mg	21890
GMP-Bios-ab-020-100mg	100mg	148000
GMP-Bios-ab-020-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-MSLN therapeutic antibody (Pre-made Amatuximab biosimilar,Whole mAb)
INN Name	Amatuximab
Target	MSLN
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	4f33:BA:DC:FE:HG/4f3f:BA
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Eisai Co Ltd;Morphotek;National Cancer Institute (USA)
Conditions Approved	na
Conditions Active	Mesothelioma
Conditions Discontinued	Pancreatic cancer;Solid tumours
Development Tech	na